LENZ Therapeutics Inc LENZ.OQ LENZ.O is expected to show a rise in quarterly revenue when it reports results on March 24 for the period ending December 31 2025
The Solana Beach California-based company is expected to report revenue of $1.886 million, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for LENZ Therapeutics Inc is for a loss of 97 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for LENZ Therapeutics Inc is $52.00, about 352.6% above its last closing price of $11.49
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.67 | -0.71 | -0.59 | Beat | 16.5 |
Jun. 30 2025 | -0.63 | -0.61 | -0.51 | Beat | 16.4 |
Mar. 31 2025 | -0.54 | -0.55 | -0.53 | Beat | 4.2 |
Dec. 31 2024 | -0.41 | -0.46 | Missed | -11.3 | |
Sep. 30 2024 | -0.46 | -0.46 | -0.38 | Beat | 18.2 |
Jun. 30 2024 | -0.50 | -0.49 | -0.40 | Beat | 18 |
Mar. 31 2024 | -0.62 | -0.84 | -3.53 | Missed | -319.4 |
Dec. 31 2023 | -0.90 | -2.80 | Missed | -210.1 |
This summary was machine generated March 20 at 11:18 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments